Immunobiology of TNFSF15 and TNFRSF25

Immunologic Research

Volumn 57, Issue 1-3, 2013, Pages 3-11

  Schreiber, Taylor H ^a   Podack, Eckhard R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant; Costimulation; DR3; FoxP3; Immunotherapy; T cell; TL1A; TNFRSF25; TNFSF15; Treg

Indexed keywords

ANTIGEN; DEATH RECEPTOR 3; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CLONAL VARIATION; EFFECTOR CELL; HUMAN; IMMUNITY; IMMUNOBIOLOGY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; RISK REDUCTION; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84891495940     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8465-0     Document Type: Article

References (51)

1. Bamias G, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868-74.
2. Bull MJ, et al the death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med. 2008;205:2457-64.
3. Cassatella MA, et al. Soluble TNF-like cytokine (TL1A) production by immune complexes stimulated monocytes in rheumatoid arthritis. J Immunol. 2007;178:7325-33.
4. Meylan F, et al the TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity. 2008;29:79-89.
5. Migone TS, et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479-92.
6. Pappu BP, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med. 2008;205:1049-62.
7. Takedatsu H, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008;135:552-67.
8. Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 2008;205:1037-48.
9. Schreiber TH, Wolf D, Podack ER the role of TNFRSF25: TNFSF15 in disease and health? Adv Exp Med Biol. 2011;691:289-98.
10. Kitson J, et al. A death-domain-containing receptor that mediates apoptosis. Nature. 1996;384:372-5.
11. Chinnaiyan AM, et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science. 1996;274:990-2.
12. Bodmer JL, et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). Immunity. 1997;6:79-88.
13. Screaton GR, et al. LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing. Proc Natl Acad Sci USA. 1997;94:4615-9.
14. Tan KB, et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene. 1997;204:35-46.
15. Marsters SA, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol. 1996;6:1669-76.
16. Wang EC, Kitson J, Thern A, Williamson J, Farrow SN, Owen MJ. Genomic structure, expression, and chromosome mapping of the mouse homologue for the WSL-1 (DR3, Apo3, TRAMP, LARD, TR3, TNFRSF12) gene. Immunogenetics. 2001;53:59-63.
17. Schreiber TH, et al therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. J Clin Investig. 2010;120:3629-40.
18. Warzocha K, Ribeiro P, Charlot C, Renard N, Coiffier B, Salles G. A new death receptor 3 isoform: expression in human lymphoid cell lines and non-Hodgkin's lymphomas. Biochem Biophys Res Commun. 1998;242:376-9.
19. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-8.
20. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181-90.
21. Wen L, Zhuang L, Luo X, Wei P. TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells. J Biol Chem. 2003;278:39251-8.
22. Wang EC, Thern A, Denzel A, Kitson J, Farrow SN, Owen MJ. DR3 regulates negative selection during thymocyte development. Mol Cell Biol. 2001;21:3451-61.
23. Al-Lamki RS, et al. TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol. 2008;19:953-60.
24. Bamias G, et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci USA. 2006;103:8441-6.
25. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR the T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells. J Immunol. 2007;178:4033-8.
26. Jin T, Guo F, Kim S, Howard A, Zhang YZ. X-ray crystal structure of TNF ligand family member TL1A at 2.1A. Biochem Biophys Res Commun. 2007;364:1-6.
27. Papadakis KA, et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol. 2004;172:7002-7.
28. Prehn JL, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol. 2004;112:66-77.
29. Papadakis KA, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol. 2005;174:4985-90.
30. Thiebaut R, et al. TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol. 2009;104:384-91.
31. Yamazaki K, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet. 2005;14:3499-506.
32. Kugathasan S, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet. 2008;40:1211-5.
33. Kakuta Y, Kinouchi Y, Negoro K, Takahashi S, Shimosegawa T. Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Gut. 2006;55:1527-8.
34. Kakuta Y, et al. TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells. Hum Mol Genet. 2009;18:1089-98.
35. Zinovieva E, et al. Comprehensive linkage and association analyses identify haplotype, near to the TNFSF15 gene, significantly associated with spondyloarthritis. PLoS Genet. 2009;5:e1000528.
36. Zhang FR, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361:2609-18.
37. Nakamura M, et al. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012;91:721-8.
38. Kayamuro H, et al. TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. Biochem Biophys Res Commun. 2009;384:296-300.
39. Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, Targan SR. TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets. J Clin Immunol. 2010;30:531-8.
40. Slebioda TJ, et al. Triggering of TNFRSF25 promotes CD8(+) T-cell responses and anti-tumor immunity. Eur J Immunol. 2011;41:2606-11.
41. Schreiber TH, Wolf D, Bodero M, Gonzalez L, Podack ER. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J Immunol. 2012;189:3311-8.
42. Khan SQ, Tsai MS, Schreiber TH, Wolf D, Deyev VV, Podack ER. Cloning, expression, and functional characterization of TL1A-Ig. J Immunol. 2013;190:1540-50.
43. Meylan F, et al the TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4:172-85.
44. Taraban VY, et al. Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol. 2011;4:186-96.
45. JR PB, et al. TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. J Virol. 2012;86:10606-20.
46. Wolf D, et al. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation. 2012;94:569-74.
47. Sauer S, et al. T cell receptor signaling controls Foxp3 expression via PI3 K, Akt, and mTOR. Proc Natl Acad Sci USA. 2008;105:7797-802.
48. Chinen T, Volchkov PY, Chervonsky AV, Rudensky AY. A critical role for regulatory T cell-mediated control of inflammation in the absence of commensal microbiota. J Exp Med. 2010;207:2323-30.
49. Barnes MJ, Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009;31:401-11.
50. Vu MD, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110:2501-10.
51. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology. 2012;1:642-8.